top of page

Regarding the selection of JAXA grant funding

April 15, 2024

In January 2024, our company representative, Kazuhiro Matsuda, applied for a position from the Japan Aerospace Exploration Agency (JAXA) in his capacity as a visiting professor at Shizuoka Institute of Science and Technology, and has now received notification of official acceptance.

  

This open call is a project to support experiments in space for the crystallization of mycoplasma glycolipid antigen synthase, which we are currently developing, where more precise crystallization is expected to be achieved than on Earth.

In addition to developing vaccines to combat mycoplasma infections, we are also focusing on developing effective low molecular weight compounds against mycoplasma infections, using the crystallization of glycolipid antigen synthase as a breakthrough.

 

Regarding mycoplasma, there is a problem of an increase in bacteria resistant to existing antibacterial drugs, but this could be a solution to that problem.

If we are successful in crystallizing mycoplasmal glycolipid antigen synthase, it will be possible to discover low molecular weight compounds that inhibit the activity of this synthase, which may enable the development of new drugs with a mechanism of action different from that of antibacterial agents.

Commentaires


bottom of page